New Step by Step Map For P-gb-IN-1
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research to evaluate various intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Primary demo goals were being To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis in